Amgen Five Prime: Gastric Cancer Deal
X
About Rama SmartSearch
RamaOnHealthcare brings signal to noise to keep you up-to-date with the latest healthcare industry news. We continuously refine our search algorithm to help you quickly and easily find the most relevant and human-vetted content from the best sources and authors.
Smart Topics: Rama SmartSearch identifies popular industry keywords as “Smart Topics” and searches article titles for related industry keywords.
You may simply combine keywords to narrow search results. Alternatively, you may use the “AND” operator to also combine keywords.
Search Example: Combine Keywords
You may use the “OR” operator to broaden search results to match one or more keywords. Alternatively, you may use the “|” operator to also broaden search results.
Search Example: “OR” Search
You may use quotes to find exact matches, where the keywords are matched in order.
Search Example: Exact Match
You may use the dash operator to exclude keywords and quoted exact matches from search results.
Search Example: Exclude Keywords
Searching…
pharmaphorum July 1, 2025
Four years after buying Five Prime for $1.9 billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal.
The new data comes from the FORTITUDE-101 looking at bemarituzumab plus chemotherapy as a front-line therapy for FGFR2b-positive advanced gastric cancer, and has revealed a significant improvement in overall survival (OS) compared to placebo plus chemo.
FGFR2b – fibroblast growth factor receptor 2b – is an emerging biomarker that is particularly prominent in gastric cancer and gastroesophageal junction (GEJ) cancer, occurring in around 38% of cases, and seems to promote the proliferation of tumour cells.
Bemarituzumab is directed against the receptor and is designed to inhibit the signalling pathways promoting tumour…
Today’s Sponsors
Today’s Sponsor
Related Articles:
2025-07-01T17:03:44-04:00